Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

1.3K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.3K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

391
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
391
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

928
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
928
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

1.1K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.1K
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

407
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
407
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

1.4K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decreased proliferation of HepG2 liver cancer cells in vitro and exhibited proteomic changes in vivo in subjects with metabolic syndrome and metabolic dysfunction-associated steatotic liver disease who performed four-week dawn-to-dusk dry fasting.

Clinical proteomics·2025
Same author

Terlipressin use in hepatorenal syndrome-acute kidney injury in cirrhosis.

Intensive care medicine·2024
Same author

Dawn-to-dusk dry fasting decreases circulating inflammatory cytokines in subjects with increased body mass index.

Metabolism open·2024
Same author

Evaluation of novel candidate filtration markers from a global metabolomic discovery for glomerular filtration rate estimation.

Kidney international·2023
Same author

Dawn-to-dusk dry fasting induces anti-atherosclerotic, anti-inflammatory, and anti-tumorigenic proteome in peripheral blood mononuclear cells in subjects with metabolic syndrome.

Metabolism open·2022
Same author

Editorial: The model of Ramadan diurnal intermittent fasting: Unraveling the health implications - volume I.

Frontiers in nutrition·2022

Related Experiment Video

Updated: Feb 28, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.8K

New Developments in Hepatorenal Syndrome.

Ayse L Mindikoglu1, Stephen C Pappas2

  • 1Michael E. DeBakey Department of Surgery, Division of Abdominal Transplantation, Baylor College of Medicine, Houston, Texas; Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|June 13, 2017
PubMed
Summary
This summary is machine-generated.

Hepatorenal syndrome (HRS) in cirrhosis is hard to diagnose due to unreliable kidney function tests. New biomarkers and diagnostic criteria may improve early detection and treatment of this serious complication.

Keywords:
CirrhosisCystatin CHepatorenal SyndromeMeta-AnalysisTerlipressin

More Related Videos

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.6K
Analysis of Nephron Composition and Function in the Adult Zebrafish Kidney
08:53

Analysis of Nephron Composition and Function in the Adult Zebrafish Kidney

Published on: August 9, 2014

45.5K

Related Experiment Videos

Last Updated: Feb 28, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.8K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.6K
Analysis of Nephron Composition and Function in the Adult Zebrafish Kidney
08:53

Analysis of Nephron Composition and Function in the Adult Zebrafish Kidney

Published on: August 9, 2014

45.5K

Area of Science:

  • Hepatology
  • Nephrology
  • Gastroenterology

Background:

  • Hepatorenal syndrome (HRS) is a severe complication of decompensated cirrhosis, often fatal without liver transplantation.
  • Accurate assessment of renal function in cirrhosis is challenging due to limitations of serum creatinine (Cr) and current glomerular filtration rate (GFR) estimation models.
  • Existing diagnostic criteria for HRS rely on excluding other kidney injuries and have limitations in differentiating HRS from other conditions.

Purpose of the Study:

  • To review the challenges in diagnosing and managing hepatorenal syndrome (HRS) in patients with cirrhosis.
  • To discuss advancements in diagnostic criteria and biomarkers for earlier identification of renal dysfunction.
  • To explore the pathophysiology and current treatment strategies for HRS.

Main Methods:

  • Review of current literature on hepatorenal syndrome (HRS) diagnosis, pathophysiology, and treatment.
  • Analysis of limitations in traditional renal function assessment (serum creatinine, GFR models) in cirrhosis.
  • Evaluation of newer diagnostic approaches including updated HRS criteria and biomarkers.
  • Discussion of the role of vasopressor therapy, albumin, liver transplantation, and other interventions.

Main Results:

  • Newer GFR models incorporating biomarkers like Cystatin C may offer more accurate renal function estimation in cirrhosis.
  • Revised HRS diagnostic criteria, focusing on dynamic serum Cr changes, aid in identifying HRS type 1 as a form of acute kidney injury.
  • Vasopressor therapy (terlipressin, noradrenaline) with albumin is effective in improving renal function and reversing HRS type 1.
  • Liver transplantation remains the definitive treatment for HRS, with increased rates of simultaneous liver-kidney transplantation.

Conclusions:

  • Accurate assessment of renal function in cirrhosis remains a significant clinical challenge.
  • Advancements in diagnostic criteria and biomarkers hold promise for earlier HRS detection and management.
  • Effective medical management of HRS involves vasopressors and albumin, but liver transplantation is curative.
  • Predicting native kidney recovery post-liver transplantation is crucial for optimizing transplant decisions.